# A Phase 1 Clinical Study to Evaluate the Effects of SHR7280 on the Pharmacokinetics of Midazolam, S-warfarin, Omeprazole, Digoxin, and Rosuvastatin in Healthy Subjects

> **NCT06949124** · PHASE1 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 20 (actual)

## Conditions studied

- Endometriosis
- Uterine Fibroids
- Assisted Reproduction

## Interventions

- **DRUG:** SHR7280 Tablets

## Key facts

- **NCT ID:** NCT06949124
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-04-28
- **Primary completion:** 2025-06-05
- **Final completion:** 2025-06-05
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06949124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06949124, "A Phase 1 Clinical Study to Evaluate the Effects of SHR7280 on the Pharmacokinetics of Midazolam, S-warfarin, Omeprazole, Digoxin, and Rosuvastatin in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06949124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*